BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-12
321 industry Phase 2/3 trial readout(s) and 51 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-12 est. | P2 | US Oncology Research | NCT00248287 PhII ICb With/Without Erbitux in MBC Pts | Metastatic Breast Cancer | active not recruiting | 154 |
| 2025-12 est. | P3 | Cell>Point LLC | NCT01394679 A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer | Lung Cancer | not yet recruiting | 154 |
| 2025-12 est. | P2 | Cell>Point LLC | NCT01899833 Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD) | Coronary Artery Disease | not yet recruiting | 60 |
| 2025-12 est. | P3 | Aesculap Biologics, LLC | NCT01957722 NOVOCART®3D for Treatment of Articular Cartilage of the Knee | Articular Cartilage of the Femoral Condyle Between 2-6cm2 | active not recruiting | 233 |
| 2025-12 est. | P2 | Candel Therapeutics, Inc. CADL | NCT02446093 Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | unknown | 54 |
| 2025-12 est. | P3 | Precision Life Sciences Group DTIL | NCT02546102 Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | Glioblastoma Multiforme | suspended | 234 |
| 2025-12 est. | P3 | Rakuten Medical, Inc. | NCT03769506 ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | Head and Neck Cancer | active not recruiting | 135 |
| 2025-12 est. | P3 | Sellas Life Sciences Group SLS | NCT04229979 Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | Acute Myeloid Leukemia | active not recruiting | 127 |
| 2025-12 est. | P2 | Intervene Immune, Inc. | NCT04375657 Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial | Epigenetic Aging; Immunosenescence | recruiting | 85 |
| 2025-12 est. | P3 | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | NCT04520412 A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease | Alzheimer Disease | suspended | 2046 |
| 2025-12 est. | P2 | Healios K.K. | NCT04533464 MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome | Trauma; Adult Stem Cells | unknown | 156 |
| 2025-12 est. | P1/P2 | Karyopharm Therapeutics Inc KPTIQ | NCT04607772 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DL | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | |
| 2025-12 est. | P1/P2 | Shanghai HEP Pharmaceutical Co., Ltd. | NCT04662164 A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin | Type 2 Diabetes Patients | withdrawn | |
| 2025-12 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT04716114 A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated | Acute Myeloid Leukemia (AML) | unknown | 315 |
| 2025-12 est. | P2 | Philogen S.p.A. | NCT04733183 Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma | Soft Tissue Sarcoma | active not recruiting | 98 |
| 2025-12 est. | P2 | UBP Greater China (Shanghai) Co., Ltd | NCT04979975 Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes | Recurrent Genital Herpes | not yet recruiting | 200 |
| 2025-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05020457 SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. | Non Small Cell Lung Cancer | active not recruiting | 69 |
| 2025-12 est. | P2/P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05020769 SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. | Non-small Cell Lung Cancer | active not recruiting | 14 |
| 2025-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05022654 SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | Esophageal Squamous Cell Carcinomas | active not recruiting | 22 |
| 2025-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05044897 A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC | Head and Neck Squamous Cell Carcinoma | active not recruiting | 11 |
| 2025-12 est. | P2/P3 | Taiwan Liposome Company | NCT05161637 Phase 2/3 Study of TLC590 for Postsurgical Pain Management | Postsurgical Pain Management | unknown | 415 |
| 2025-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05192486 A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | active not recruiting | 12 |
| 2025-12 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05216965 A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors | Solid Tumors | unknown | 208 |
| 2025-12 est. | P1/P2 | Salarius Pharmaceuticals, LLC | NCT05266196 A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | Ewing Sarcoma; Myxoid Liposarcoma; Desmoplastic Small Round Cell Tumor; Extraskeletal Myxoid Chondro | unknown | 10 |
| 2025-12 est. | P1/P2 | Biolingus | NCT05268237 Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus | Diabete Type 2 | recruiting | 15 |
| 2025-12 est. | P1/P2 | Sorrento Therapeutics, Inc. | NCT05308225 Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | unknown | 72 |
| 2025-12 est. | P2/P3 | Kibow Pharma | NCT05407389 Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR202 | Chronic Kidney Disease stage4 | suspended | 600 |
| 2025-12 est. | P1/P2 | Eleusis Therapeutics | NCT05434156 ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression | Healthy Volunteers; Major Depressive Disorder; Depression | active not recruiting | 84 |
| 2025-12 est. | P2 | PhytoHealth Corporation | NCT05440227 PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients | Cancer-related Fatigue | recruiting | 36 |
| 2025-12 est. | P2 | Biocad | NCT05445076 Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis | Axial Spondyloarthritis | active not recruiting | 250 |
| 2025-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05485753 A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous Sys | Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma | active not recruiting | 7 |
| 2025-12 est. | P1/P2 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | NCT05525715 A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | unknown | 260 |
| 2025-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05627856 A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL | NK/T Cell Lymphoma; Vascular Immunomother T Cell Lymphoma; Non-Hodgkin Lymphoma | active not recruiting | 4 |
| 2025-12 est. | P3 | IBSA Institut Biochimique SA | NCT05632783 TreatMent Of Knee osTeoarthritis wIth chONdroitin Sulfate - the OA MOTION Study | Knee Osteoarthritis | withdrawn | |
| 2025-12 est. | P2 | RemeGen Co., Ltd. | NCT05680480 A Study of Telitacicept in Lupus Nephritis | Lupus Nephritis | unknown | 120 |
| 2025-12 est. | P2 | Omeros Corporation OMER | NCT05855083 Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA | Thrombotic Microangiopathies; Hematopoietic Stem Cell Transplantation | recruiting | 18 |
| 2025-12 est. | P1/P2 | HuidaGene Therapeutics Co., Ltd. | NCT05906953 Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR) | Leber Congenital Amaurosis; Inherited Retinal Diseases Caused by RPE65 Mutations | unknown | 20 |
| 2025-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05944978 A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies | Relapsed/Refractory Chronic Lymphocytic Leukemia | active not recruiting | 3 |
| 2025-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05949619 A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors | Non-small Cell Lung Cancer | active not recruiting | 14 |
| 2025-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05959694 A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Ly | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | unknown | 107 |
| 2025-12 est. | P2 | Glaukos Corporation GKOS | NCT05966493 A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED | Persistent Corneal Epithelial Defect | recruiting | 84 |
| 2025-12 est. | P1/P2 | CNBG-Virogin Biotech (Shanghai) Ltd. | NCT06008925 Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer | Metastatic Gastric Cancer | unknown | 43 |
| 2025-12 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06092268 A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | Advanced Solid Tumors | unknown | 270 |
| 2025-12 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06104553 A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma | B-cell Non-Hodgkin's Lymphoma | unknown | 132 |
| 2025-12 est. | P1/P2 | Affini-T Therapeutics, Inc. | NCT06105021 Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Pancreatic Ductal Adenocarcinoma; Non-Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor; KRAS G | active not recruiting | 100 |
| 2025-12 est. | P3 | Clinuvel, Inc. CUVL | NCT06109649 A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo | Vitiligo | active not recruiting | 200 |
| 2025-12 est. | P3 | Shanghai Yizhong Pharmaceutical Co., Ltd. | NCT06143553 Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer | Metastatic Breast Cancer (MBC) | unknown | 168 |
| 2025-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06150014 A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatiti | Chronic Hepatitis b | active not recruiting | 88 |
| 2025-12 est. | P1/P2 | iRegene Therapeutics Co., Ltd. | NCT06167681 The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease | Parkinson Disease | recruiting | 40 |
| 2025-12 est. | P1/P2 | Biocad | NCT06185335 A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A | Hemophilia A | active not recruiting | 50 |
| 2025-12 est. | P2 | RemeGen Co., Ltd. | NCT06227117 Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | Breast Cancer | recruiting | 120 |
| 2025-12 est. | P2 | RemeGen Co., Ltd. | NCT06227156 Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer | unknown | 40 |
| 2025-12 est. | P2 | Rege Nephro Co., Ltd. | NCT06289998 Study of Tamibarotene in Patients With ADPKD | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | active not recruiting | 70 |
| 2025-12 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06313086 DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer | HER2-positive Breast Cancer | recruiting | 442 |
| 2025-12 est. | P3 | Tianjin Hemay Pharmaceutical Co., Ltd | NCT06313983 A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | Breast Cancer | recruiting | 339 |
| 2025-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06385678 A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Advanced KRAS G12D Mutant Solid Tumors | active not recruiting | 47 |
| 2025-12 est. | P2 | PHARMENTERPRISES LLC | NCT06391164 Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis | Cystitis | unknown | 280 |
| 2025-12 est. | P2 | Spinogenix | NCT06427668 Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD) | Alzheimer Disease | active not recruiting | 24 |
| 2025-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06434467 The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma | T-lymphoblastic Leukemia; T-lymphoblastic Lymphoma | unknown | 83 |
| 2025-12 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06439589 Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | Advanced Solid Tumors | unknown | 88 |
| 2025-12 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06565871 A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea | Weight Management | unknown | 108 |
| 2025-12 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06595797 A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Su | Obese Subjects With Polycystic Ovary Syndrome (PCOS) | unknown | 144 |
| 2025-12 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06639295 A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Sinusitis; Nasal Polyps | active not recruiting | 243 |
| 2025-12 est. | P3 | Biocad | NCT06640530 Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | Advanced Melanoma; Melanoma (Skin) | active not recruiting | 392 |
| 2025-12 est. | P2 | SynAct Pharma Aps | NCT06671054 A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Partic | Rheumatoid Arthritis (RA) | recruiting | 240 |
| 2025-12 est. | P2 | Gilead Sciences GILD | NCT06682234 Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease | Filovirus Disease; Postexposure Prophylaxis for Filovirus Disease | withdrawn | |
| 2025-12 est. | P2 | Verastem, Inc. VSTM | NCT06682572 A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | Low Grade Serous Ovarian Cancer; Ovarian Cancer | active not recruiting | 16 |
| 2025-12 est. | P1/P2 | Zhuhai Beihai Biotech Co., Ltd | NCT06732531 Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | Bladder Cancer; Non Muscle Invasive | recruiting | 48 |
| 2025-12 est. | P1/P2 | Herbarium Laboratorio Botanico Ltda | NCT06751433 Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars | Acceptability Study; Real-use Conditions; Safety and Efficacy; Topical Administration; Hypertrophic | recruiting | 80 |
| 2025-12 est. | P2 | Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. | NCT06852976 A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care | Diabetic Foot Ulcer | recruiting | 60 |
| 2025-12 est. | P2 | Jina Pharmaceuticals Inc. | NCT06867042 Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to th | Ulcerative Colitis (UC); Ulcerative Colitis, Active Moderate | not yet recruiting | 150 |
| 2025-12 est. | P3 | Jina Pharmaceuticals Inc. | NCT06867562 Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer | Platinum-Resistant Primary Peritoneal Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Ca | not yet recruiting | 166 |
| 2025-12 est. | P1/P2 | STCube, Inc. | NCT06873763 Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer | Metastatic Colorectal Cancer (CRC); Recurrent Colorectal Cancer | recruiting | 52 |
| 2025-12 est. | P1/P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07008703 Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain | Cancer Pain | recruiting | 132 |
| 2025-12 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT07028268 A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors | For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors | recruiting | 210 |
| 2025-12 est. | P2 | Biocad | NCT07108309 BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer | Triple Negative Breast Cancer | recruiting | 124 |
| 2025-12 est. | P2 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT07133815 Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | Homozygous Familial Hypercholesterolemia | not yet recruiting | 55 |
| 2025-12 est. | P2 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | NCT07147049 Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery | Moderate to Severe Acute Postoperative Pain | recruiting | 72 |
| 2025-12 est. | P2 | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | NCT07179653 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatit | HBV Infection | active not recruiting | 48 |
| 2025-12-01 | P3 | BeiGene | NCT03519230 Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer | Ovarian Cancer | active not recruiting | 224 |
| 2025-12-01 | P3 | AbbVie ABBV | NCT04760769 Open-label Trial in Parkinson's Disease (PD) | Parkinson Disease | completed | 992 |
| 2025-12-01 est. | P2 | Khondrion BV | NCT04846036 The KHENERGYC Study | Mitochondrial Diseases; Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation; MELAS; Subacute Necrotizi | suspended | 24 |
| 2025-12-01 est. | P1/P2 | Ectin Research AB | NCT05390645 A Study of MFA-370 in Patients with Metastatic Urothelial Cancer | Metastatic Urothelial Cancer | withdrawn | |
| 2025-12-01 | P1/P2 | SignalChem Lifesciences Corporation | NCT05860296 Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | Lung Cancer, Nonsmall Cell; Lung Cancer Stage IV; Lung Cancer Metastatic | terminated | 36 |
| 2025-12-01 est. | P2 | RemeGen Co., Ltd. | NCT05943379 RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | NMIBC | recruiting | 85 |
| 2025-12-01 est. | P2/P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05945901 A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab | Colorectal Cancer | active not recruiting | 669 |
| 2025-12-01 | P2 | Shuttle Pharmaceuticals, Inc. SHPH | NCT06359379 Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter | Glioblastoma, IDH-wildtype | terminated | 30 |
| 2025-12-01 est. | P2 | Distribuidora Biolife SA de CV | NCT06520878 Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment | Cognition | recruiting | 60 |
| 2025-12-01 | P1/P2 | Fenix Innovation Group | NCT06621043 Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT) | Rett Syndrome | completed | 14 |
| 2025-12-01 | P1/P2 | Fenix Innovation Group | NCT06621888 Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) | PANS Pediatric Acute-Onset Neuropsychiatric Syndrome | completed | 18 |
| 2025-12-01 est. | P2 | Hansoh BioMedical R&D Company | NCT06635772 A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy | Immunoglobulin a Nephropathy | unknown | 90 |
| 2025-12-01 est. | P1/P2 | Biosergen AS | NCT06678113 Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection | Invasive Fungal Infection | unknown | 15 |
| 2025-12-01 | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07091357 A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | completed | 108 |
| 2025-12-02 | P1/P2 | Synthorx, Inc, a Sanofi company | NCT04009681 A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | Metastasis | terminated | 175 |
| 2025-12-02 | P1/P2 | Ascendis Pharma Oncology Division A/S ASND | NCT04799054 A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Head and Neck Squamous C | terminated | 188 |
| 2025-12-02 | P2 | Hoffmann-La Roche | NCT05630066 A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angel | Angelman Syndrome | completed | 48 |
| 2025-12-02 | P2 | Allodynic Therapeutics, Inc | NCT05685225 Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial | Migraine | withdrawn | |
| 2025-12-02 | P3 | Boehringer Ingelheim | NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Obesity | completed | 726 |
| 2025-12-03 | P2 | AGO Research GmbH | NCT04274426 Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer | Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | active not recruiting | 136 |
| 2025-12-03 | P2/P3 | Immunome, Inc. IMNM | NCT04871282 A Study of AL102 in Patients With Progressing Desmoid Tumors | Desmoid; Desmoid Tumor | active not recruiting | 198 |
| 2025-12-03 | P1/P2 | Bristol-Myers Squibb BMY | NCT05255601 A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and | Lymphoma, Non-Hodgkin; Hodgkin Disease | terminated | 5 |
| 2025-12-03 | P3 | Boehringer Ingelheim | NCT06176365 A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease | Obesity | completed | 274 |
| 2025-12-03 | P1/P2 | Therapex Co., Ltd | NCT06186076 A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients | Carcinoma, Non-Small-Cell Lung; EGFR Mutant Advanced Non-Small Cell Lung Cancer | terminated | 19 |
| 2025-12-03 | P2 | AstraZeneca AZN | NCT06595238 A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity | Obesity or Overweight | completed | 262 |
| 2025-12-03 | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT06786455 Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Sin | Adolescent Asthma | completed | 9 |
| 2025-12-03 | P2 | PHARMAFINA | NCT07131657 Ropiclobet for Regional Anesthesia and Post-Operative Pain Control in Upper Extremity Surgery | Nerve Block; Upper Extremity Surgery | completed | 40 |
| 2025-12-04 | P3 | Eli Lilly and Company LLY | NCT04396574 A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | Migraine | terminated | 558 |
| 2025-12-04 | P2 | Sustained Therapeutics Inc. | NCT05707208 A Randomized, Controlled Study of Repeat Dose Sustained Release Lidocaine for Treatment of Chronic Scrotal Pain | Chronic Pain | completed | 63 |
| 2025-12-04 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06252285 Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers | RSV Immunisation | terminated | 6300 |
| 2025-12-04 | P2 | Arcutis Biotherapeutics, Inc. ARQT | NCT06998056 Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis | Atopic Dermatitis (Eczema) | completed | 101 |
| 2025-12-05 | P1/P2 | Dragonfly Therapeutics DFLI | NCT04143711 Study of DF1001 in Patients With Advanced Solid Tumors | Solid Tumor, Adult | completed | 270 |
| 2025-12-05 est. | P3 | Xuanzhu Biopharmaceutical Co., Ltd. | NCT05257395 A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer | Advanced Breast Cancer | active not recruiting | 397 |
| 2025-12-05 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT05342636 A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | Esophageal Squamous Cell Carcinoma (ESCC) | completed | 90 |
| 2025-12-05 | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT05593250 A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma | Asthma | completed | 260 |
| 2025-12-05 | P3 | AbbVie ABBV | NCT05818709 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants | Facial Volume Deficit | completed | 61 |
| 2025-12-06 | P2 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | NCT06901830 A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery | Pain | completed | 150 |
| 2025-12-07 | P3 | Foresee Pharmaceuticals Co., Ltd. | NCT05493709 Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty | Puberty; Precocious, Central | completed | 94 |
| 2025-12-07 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06706310 Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection | Chronic Hepatitis B | active not recruiting | 116 |
| 2025-12-08 | P3 | Areteia Therapeutics | NCT05763121 A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. | Eosinophilic Asthma; Asthma; Eosinophilic; Asthma | terminated | 1061 |
| 2025-12-08 | P3 | Areteia Therapeutics | NCT05813288 A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) | Eosinophilic Asthma; Asthma; Eosinophilic; Asthma | terminated | 654 |
| 2025-12-08 | P2 | Eli Lilly and Company LLY | NCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | completed | 164 |
| 2025-12-08 | P3 | Novo Nordisk A/S NVO | NCT06131437 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | Obesity | completed | 809 |
| 2025-12-08 | P3 | Areteia Therapeutics | NCT06388889 Phase III Long-Term Extension Study With Dexpramipexole | Eosinophilic Asthma | terminated | 509 |
| 2025-12-08 | P2 | Carmot Therapeutics, Inc. | NCT06525935 A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity | Obesity; Overweight | completed | 469 |
| 2025-12-08 | P1/P2 | Sinovac Life Sciences Co., Ltd. | NCT06939777 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants | Tetanus | completed | 255 |
| 2025-12-08 | P2 | Ascletis Pharma (China) Co., Limited | NCT07002905 A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities | Chronic Weight Management | completed | 125 |
| 2025-12-09 | P2 | Takeda TAK | NCT04530123 Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Fre | Celiac Disease | completed | 102 |
| 2025-12-09 | P2 | Chiesi Farmaceutici S.p.A. | NCT06029595 Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy | Uncontrolled Asthma | terminated | 517 |
| 2025-12-09 | P3 | Rose Research Center, LLC | NCT06554873 Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders | Smoking Cessation; Harm Reduction | completed | 150 |
| 2025-12-10 | P3 | Eli Lilly and Company LLY | NCT04616326 A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | Chronic Migraine | active not recruiting | 312 |
| 2025-12-10 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT04786574 A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycyst | Autosomal Recessive Polycystic Kidney Disease (ARPKD) | withdrawn | |
| 2025-12-10 est. | P3 | Swedish Orphan Biovitrum | NCT05814159 A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD) | Still's Disease, Juvenile Onset; Still's Disease, Adult-Onset | active not recruiting | 15 |
| 2025-12-10 | P1/P2 | S.Biomedics Co., Ltd. | NCT05887466 Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients | Parkinson's Disease | completed | 12 |
| 2025-12-10 | P2 | atai Therapeutics, Inc. | NCT06693609 Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder | Social Anxiety Disorder | completed | 70 |
| 2025-12-11 | P3 | Colgate Palmolive CL | NCT07134231 Clinical Study to Evaluate the Anti-cavity Efficacy of Three Dentifrices: An In Situ Model | Demineralization; Remineralization; Dental Cavity; Enamel Lesions | completed | 36 |
| 2025-12-12 est. | P2 | ONY | NCT04056741 Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study | RDS of Prematurity; Surfactant Protein B Deficiency; Chronic Lung Disease | suspended | 55 |
| 2025-12-12 est. | P2 | Hansoh BioMedical R&D Company | NCT06007729 ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | Head and Neck Squamous Cell Carcinoma | recruiting | 170 |
| 2025-12-12 | P3 | Boehringer Ingelheim | NCT06058793 Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma | Liposarcoma, Dedifferentiated | completed | 138 |
| 2025-12-12 | P3 | Boehringer Ingelheim | NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight | Obesity; Diabetes Mellitus, Type 2 | completed | 755 |
| 2025-12-12 est. | P2 | Shanghai Jiatan Pharmatech Co., Ltd | NCT06124963 A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations | Gastric Type Adenocarcinoma (GAS) With STK11 Mutation | recruiting | 20 |
| 2025-12-12 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06168383 To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) . | Non-Alcoholic Steatohepatitis (NASH) | completed | 186 |
| 2025-12-12 | P3 | Apellis Pharmaceuticals, Inc. | NCT07214740 Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe | Geographic Atrophy Secondary to Age-related Macular Degeneration | completed | 44 |
| 2025-12-15 | P2 | TYK Medicines, Inc | NCT05948813 TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases | NSCLC; EGFR Activating Mutation; Brain Metastases | recruiting | 420 |
| 2025-12-15 est. | P2 | Suzhou Alphamab Co., Ltd. | NCT06180889 Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty | Knee Arthroplasty, Total | active not recruiting | 241 |
| 2025-12-15 | P3 | argenx ARGX | NCT06307613 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease | Thyroid Eye Disease | terminated | 102 |
| 2025-12-15 | P3 | argenx ARGX | NCT06307626 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. | Thyroid Eye Disease | terminated | 105 |
| 2025-12-15 | P2 | Eli Lilly and Company LLY | NCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Obesity | completed | 392 |
| 2025-12-15 | P2 | Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. | NCT06532578 Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus | Overweight and Obesity | completed | 240 |
| 2025-12-15 | P1/P2 | NexThera Co., Ltd. | NCT06704009 NT-101 Topical Ophthalmic Solution in Patients With Wet AMD | Wet Age Related Macular Degeneration; Wet AMD | completed | 20 |
| 2025-12-15 | P2 | Motric Bio | NCT06830642 Study of the Oral Treatment MTR-601 in Cervical Dystonia | Cervical Dystonia | terminated | 38 |
| 2025-12-15 | P2 | Chendu DIAO Pharmaceutical Group CO., LTD. | NCT06953063 A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects | Overweight and Obesity | completed | 250 |
| 2025-12-15 | P3 | GlaxoSmithKline | NCT06995430 A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old) | Meningitis | completed | 312 |
| 2025-12-15 est. | P2 | Shin Poong Pharmaceutical Co. Ltd. | NCT07064525 Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension | Hypertension (HTN); NYHA Class III Heart Failure; NYHA Class IV Heart Failure; Diabete Mellitus | enrolling by invitation | 252 |
| 2025-12-16 | P2 | Pfizer PFE | NCT04821310 Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years | Esophagitis | terminated | 43 |
| 2025-12-16 | P2 | CyanVac LLC | NCT05736835 A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults | COVID-19 | completed | 227 |
| 2025-12-16 | P2 | Upstream Bio Inc. UPB | NCT06196879 A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) | Severe Asthma | completed | 479 |
| 2025-12-16 | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06198426 A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Solid Tumor | terminated | 5 |
| 2025-12-16 | P3 | Hoffmann-La Roche | NCT06267001 A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Re | Non-small Cell Lung Cancer (NSCLC) | terminated | 56 |
| 2025-12-16 | P2 | Glaceum | NCT06329141 A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients | Parkinson Disease | completed | 99 |
| 2025-12-16 | P2 | Zai Lab (Hong Kong), Ltd. | NCT06380907 A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis | Plaque Psoriasis | terminated | 65 |
| 2025-12-16 | P2 | New England Cell Therapeutics, Inc. | NCT06910384 A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | terminated | 1 |
| 2025-12-16 | P2 | Pfizer PFE | NCT06973720 A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight | Obesity; Overweight or Obesity | completed | 268 |
| 2025-12-17 | P3 | Sanofi SNY | NCT05206773 A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease | Fabry Disease | active not recruiting | 122 |
| 2025-12-17 | P3 | Bellus Health Inc. - a GSK company | NCT05599191 A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough | Cough; Refractory Chronic Cough | completed | 957 |
| 2025-12-17 | P2 | Gilead Sciences GILD | NCT05629208 Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Cutaneous Lupus Erythematosus (CLE) | terminated | 20 |
| 2025-12-17 | P3 | Quince Therapeutics S.p.A. | NCT06193200 Evaluate the Neurological Effects of EryDex on Subjects With A-T | Ataxia Telangiectasia | completed | 105 |
| 2025-12-17 | P2 | Mineralys Therapeutics Inc. MLYS | NCT06785454 A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension | Obstructive Sleep Apnea; Hypertension | completed | 48 |
| 2025-12-17 | P1/P2 | BioNTech SE BNTX | NCT06821061 A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People | Influenza; COVID-19 (Coronavirus Disease 2019) | completed | 2650 |
| 2025-12-18 | P3 | QED Therapeutics, a BridgeBio company | NCT06164951 A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia | Achondroplasia | completed | 114 |
| 2025-12-18 | P2 | Orphalan | NCT07010575 Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride | Wilson's Disease | completed | 10 |
| 2025-12-19 | P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT05093634 EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | Obesity; Genetic Obesity | completed | 296 |
| 2025-12-19 | P1/P2 | Lyvgen Biopharma Holdings Limited | NCT05301764 A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma | Soft Tissue Sarcoma | completed | 39 |
| 2025-12-19 | P2 | BeiGene | NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer | completed | 418 |
| 2025-12-19 | P1/P2 | Sinovac Biotech Co., Ltd SVA | NCT06063057 Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial | Hand, Foot and Mouth Disease; Herpangina | completed | 744 |
| 2025-12-19 | P2 | Reveal Pharmaceuticals Inc. | NCT06322342 Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | Central Nervous System (CNS) Lesions; Brain Metastases; Brain Neoplasms; Brain Neoplasms, Benign; Br | completed | 18 |
| 2025-12-19 | P3 | ACADIA Pharmaceuticals Inc. ACAD | NCT06420297 OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | Hyperphagia in Prader-Willi Syndrome | terminated | 168 |
| 2025-12-19 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06439381 Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps | Chronic Rhinosinusitis | completed | 119 |
| 2025-12-19 | P3 | Boston Scientific Corporation BSX | NCT06492174 A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort | In-Stent Restenosis | active not recruiting | 20 |
| 2025-12-19 | P2 | AstraZeneca AZN | NCT06579105 Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. | Diabetes Mellitus, Type 2 | completed | 406 |
| 2025-12-19 est. | P1/P2 | AstraZeneca AZN | NCT07060365 A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent | Advanced/Recurrent Ovarian Cancer | withdrawn | |
| 2025-12-19 | P2 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | NCT07712536 Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis | Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD) | completed | 24 |
| 2025-12-20 est. | P2 | RemeGen Co., Ltd. | NCT06105008 Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer | Breast Neoplasms | withdrawn | |
| 2025-12-20 est. | P2 | Guangdong Raynovent Biotech Co., Ltd | NCT06254261 A Study of RAY1225 in Participants With Obesity | Obesity | recruiting | 270 |
| 2025-12-20 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06670352 Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN | IgA Nephropathy (IgAN) | completed | 87 |
| 2025-12-21 | P3 | Colgate Palmolive CL | NCT07225478 Clinical Study to Evaluate the Tooth Whitening Efficacy of a New NextGen In-office Whitening System | Health Adult Subjects | completed | 180 |
| 2025-12-22 | P3 | Pfizer PFE | NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Derm | Dermatitis, Atopic | completed | 3166 |
| 2025-12-22 | P3 | Merck Sharp & Dohme LLC MRK | NCT04193215 V114 and Acute Otitis Media (V114-032/PNEU-ERA) | Acute Otitis Media (AOM) | completed | 7119 |
| 2025-12-22 | P3 | Hoffmann-La Roche | NCT04629248 A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy | Primary Membranous Nephropathy | active not recruiting | 142 |
| 2025-12-22 | P1/P2 | BioNTech SE BNTX | NCT05262530 Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | Solid Tumor | terminated | 73 |
| 2025-12-22 | P1/P2 | Sanofi SNY | NCT05450562 Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | Neoplasm | terminated | 33 |
| 2025-12-22 | P2 | Sanofi SNY | NCT05704049 A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple | Relapsed/Refractory Multiple Myeloma | active not recruiting | 118 |
| 2025-12-22 est. | P3 | Shanghai Jiatan Pharmatech Co., Ltd | NCT05824871 A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients | Rifampin-Resistant Pulmonary Tuberculosis; Tuberculosis, Multidrug-Resistant (MDR-TB) | recruiting | 450 |
| 2025-12-22 est. | P1/P2 | IDP Discovery Pharma S.L. | NCT05908409 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | Multiple Myeloma (MM); Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Double Hit Lymphoma; | recruiting | 37 |
| 2025-12-22 | P1/P2 | Kyverna Therapeutics KYTX | NCT06342960 KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | Lupus Nephritis; Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV | terminated | 2 |
| 2025-12-22 | P2 | HysensBio Co., Ltd | NCT06464939 Phase 2 Study of KH001 in Long-term Relief From Dentin Hypersensitivity | Dentin Hypersensitivity | completed | 120 |
| 2025-12-22 | P3 | Amzell | NCT06693648 A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms | Osteoarthritis of Knee; Osteoarthritis, Knee | completed | 549 |
| 2025-12-22 | P2 | Enyo Pharma | NCT06939816 Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) | Chronic Kidney Disease Stage 2; Chronic Kidney Disease Stage 3; Metabolic Dysfunction-Associated Ste | terminated | 10 |
| 2025-12-22 | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT07229820 Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza A | Influenza A | completed | 157 |
| 2025-12-23 | P3 | X4 Pharmaceuticals XFOR | NCT03995108 Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | WHIM Syndrome | completed | 31 |
| 2025-12-23 | P3 | Chiesi Farmaceutici S.p.A. | NCT04636814 A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as | Chronic Obstructive Pulmonary Disease | terminated | 3973 |
| 2025-12-23 | P3 | SynOx Therapeutics Limited | NCT05417789 Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) | TGCT | active not recruiting | 128 |
| 2025-12-23 | P3 | Biocon Biologics UK Ltd | NCT06038539 Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as N | HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients | terminated | 55 |
| 2025-12-23 | P3 | Amgen AMGN | NCT06248619 A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyro | Thyroid Eye Disease | active not recruiting | 89 |
| 2025-12-23 | P3 | Haisco Pharmaceutical Group Co., Ltd. | NCT07052838 Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia | Paroxysmal Nocturnal Haemoglobinuria (PNH) | completed | 36 |
| 2025-12-24 | P1/P2 | Incyte Corporation INCY | NCT02917993 An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | Lung Cancer | completed | 59 |
| 2025-12-24 | P1/P2 | Xencor, Inc. XNCR | NCT06173505 Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Nonsquamous Non-small Cell Lung Cancer | terminated | 28 |
| 2025-12-24 | P3 | Novavax NVAX | NCT06291857 A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine | COVID-19 | completed | 9320 |
| 2025-12-25 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT07222059 Phase 3 Single Arm, Open Study on vYF in Adults | Yellow Fever | completed | 254 |
| 2025-12-26 | P3 | Sanofi SNY | NCT03485677 Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 | Gaucher's Disease Type I; Gaucher's Disease Type III | completed | 57 |
| 2025-12-26 | P2 | Hoffmann-La Roche | NCT05661578 A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Loca | PD-L1-selected Solid Tumors | completed | 64 |
| 2025-12-28 est. | P1/P2 | Letolab | NCT06384248 Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma | Unresectable or Metastatic Sarcoma | unknown | 30 |
| 2025-12-28 est. | P1/P2 | NEXBIOME THERAPEUTICS | NCT06450990 Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection | Bacterial Vaginosis; Vulvovaginal Candidiasis | unknown | 165 |
| 2025-12-29 | P3 | Pulmocide Ltd | NCT05238116 Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA | Refractory IPA | terminated | 85 |
| 2025-12-29 | P2 | Merck Sharp & Dohme LLC MRK | NCT05877547 A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Diseas | completed | 381 |
| 2025-12-29 est. | P2/P3 | Convalife (Shanghai) Co., Ltd. | NCT06293716 CVL237 Tablets for APDS/PASLI | PI3K and P110delta Hyperactivation Syndrome | unknown | 35 |
| 2025-12-29 | P2 | Axoltis Pharma | NCT06365216 ALS Phase II Study of NX210c | Amyotrophic Lateral Sclerosis | completed | 83 |
| 2025-12-29 | P3 | Bayer | NCT06422507 A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema | Diabetic Macular Edema | completed | 333 |
| 2025-12-29 | P3 | Alexion Pharmaceuticals, Inc. | NCT06764160 Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG | Generalized Myasthenia Gravis (gMG); Refractory gMG | completed | 15 |
| 2025-12-29 | P2 | Pfizer PFE | NCT06897202 A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM | Obesity in Diabetes; Type 2 Diabetes Mellitus (T2DM) | completed | 133 |
| 2025-12-29 | P1/P2 | Aurigene Discovery Technologies Limited | NCT07040059 A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Ga | HER 2 Positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | terminated | 2 |
| 2025-12-30 est. | P3 | Xcovery Holdings, Inc. | NCT02767804 eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | Non-small Cell Lung Cancer | active not recruiting | 290 |
| 2025-12-30 est. | P3 | OBI Pharma, Inc | NCT03562637 Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | Triple Negative Breast Cancer | active not recruiting | 575 |
| 2025-12-30 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT03611868 A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma; P53 Mutation | active not recruiting | 230 |
| 2025-12-30 est. | P2 | Chase Therapeutics Corporation WHLT | NCT03642964 A Study in Patients With Major Depressive Disorder | Major Depressive Disorder (MDD) | unknown | 24 |
| 2025-12-30 est. | P2 | Chase Therapeutics Corporation WHLT | NCT03683225 A Study to Evaluate in Patients With Parkinsonian Type Disorders | Idiopathic Parkinson Disease | unknown | 24 |
| 2025-12-30 | P1/P2 | Genmab GMAB | NCT04083599 GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | Malignant Solid Tumor; Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Melanoma; Head a | active not recruiting | 350 |
| 2025-12-30 | P3 | Hoffmann-La Roche | NCT04294810 A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Adv | Non-Small Cell Lung Cancer | completed | 620 |
| 2025-12-30 est. | P1/P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT04304040 A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma | B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory | unknown | 43 |
| 2025-12-30 | P1/P2 | Antengene Corporation | NCT04425070 A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-ce | Peripheral T-cell Lymphoma; NK/T-cell Lymphoma | terminated | 56 |
| 2025-12-30 est. | P3 | Akeso | NCT04982237 A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | Cervical Cancer | active not recruiting | 445 |
| 2025-12-30 est. | P1/P2 | Akeso | NCT04982276 A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | recruiting | 138 |
| 2025-12-30 | P3 | Hoffmann-La Roche | NCT05047250 A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 60 |
| 2025-12-30 est. | P1/P2 | HELP Therapeutics Co., Ltd. | NCT05223894 Treating Heart Failure With hiPSC-CMs | Heart Failure | unknown | 20 |
| 2025-12-30 est. | P2 | Tarapeutics Science Inc. | NCT05241093 A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | 18 |
| 2025-12-30 est. | P2 | Tarapeutics Science Inc. | NCT05241106 A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | 15 |
| 2025-12-30 est. | P3 | Akeso | NCT05244642 A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma | Hodgkin Disease Lymphoma | unknown | 60 |
| 2025-12-30 | P1/P2 | Tango Therapeutics, Inc. TNGX | NCT05275478 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Locally Advanced Solid Tumor | terminated | 110 |
| 2025-12-30 est. | P2 | Kintara Therapeutics, Inc. | NCT05374915 Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) | Cutaneous Breast Cancer | active not recruiting | 15 |
| 2025-12-30 | P2/P3 | Quoin Pharmaceuticals QNRX | NCT05521438 Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | active not recruiting | 30 |
| 2025-12-30 | P1/P2 | Grit Biotechnology | NCT05729399 Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors | Solid Tumor | terminated | 6 |
| 2025-12-30 est. | P3 | Telix Pharmaceuticals (Innovations) Pty Limited TLX | NCT05847348 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients | Biochemical Recurrence of Malignant Neoplasm of Prostate; Prostate Cancer; BCR Prostate Carcinoma | unknown | 110 |
| 2025-12-30 est. | P1/P2 | GI Cell, Inc. | NCT05880043 GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies | Advanced Solid Tumors; Relapsed/Refractory Non-Hodgkin Lymphoma; Relapsed/Refractory Multiple Myelom | unknown | 50 |
| 2025-12-30 est. | P3 | Energenesis Biomedical Co., Ltd. | NCT05930210 A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer | Diabetic Foot Ulcer; Foot Ulcer; Diabetes Mellitus; Wound | recruiting | 230 |
| 2025-12-30 est. | P1/P2 | Genfleet Therapeutics (Shanghai) Inc. | NCT05934513 A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | unknown | 95 |
| 2025-12-30 | P3 | Mineralys Therapeutics Inc. MLYS | NCT05968430 Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | Hypertension | active not recruiting | 1076 |
| 2025-12-30 est. | P2 | Abbisko Therapeutics Co, Ltd | NCT06111274 A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | Advanced Pancreatic Cancer | recruiting | 82 |
| 2025-12-30 est. | P1/P2 | Indapta Therapeutics, INC. | NCT06119685 IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | NHL; Multiple Myeloma; Blood Cancer; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; | recruiting | 128 |
| 2025-12-30 est. | P1/P2 | CNBG-Virogin Biotech (Shanghai) Ltd. | NCT06124001 Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | Primary Hepatocellular Carcinoma | unknown | 36 |
| 2025-12-30 | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06245941 A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) | Myelofibrosis | terminated | 21 |
| 2025-12-30 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06247956 Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer | Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma | active not recruiting | 153 |
| 2025-12-30 est. | P2/P3 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NCT06477536 Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis | Generalized Pustular Psoriasis | unknown | 33 |
| 2025-12-30 est. | P3 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | NCT06573008 Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications | Influenza, Human | recruiting | 328 |
| 2025-12-30 est. | P2/P3 | Resverlogix Corp | NCT06590324 A Study of Apabetalone in Subjects With Long -COVID | Post-Acute COVID-19 Syndrome | recruiting | 200 |
| 2025-12-30 est. | P2 | Keymed Biosciences Co.Ltd | NCT06594146 Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) | Primary Immune Thrombocytopenia | active not recruiting | 62 |
| 2025-12-30 | P1/P2 | Sinovac Biotech Co., Ltd SVA | NCT06754384 Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). | Hand, Foot, and Mouth Disease (HFMD); Herpangina | completed | 552 |
| 2025-12-30 est. | P1/P2 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | NCT06819215 Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | Cancer; Neoplasms; Neoplasms, Breast; Tumor; PARP; Ovarian Neoplasms; Prostatic Cancer; Pancreatic C | recruiting | 188 |
| 2025-12-30 est. | P3 | Wuhan Createrna Science and Technology Co., Ltd | NCT06932471 Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment | Paroxysmal Nocturnal Hemoglobinuria | recruiting | 20 |
| 2025-12-30 est. | P3 | Wuhan Createrna Science and Technology Co., Ltd | NCT06932744 Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy | Paroxysmal Nocturnal Haemoglobinuria (PNH) | recruiting | 66 |
| 2025-12-30 | P3 | Sarfez Pharmaceuticals, Inc. | NCT07015671 Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects | Bioequivalence Study in Healthy Subjects; PK/PD | completed | 24 |
| 2025-12-30 | P3 | Sarfez Pharmaceuticals, Inc. | NCT07043634 A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) T | Bioavailability Heathy Volunteers | completed | 24 |
| 2025-12-30 | P3 | Colgate Palmolive CL | NCT07210138 Clinical Investigation of PerioGard (Test) Regimen | Gingivitis | completed | 80 |
| 2025-12-30 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07252921 Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults | Neuromuscular Blockade | completed | 70 |
| 2025-12-30 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07331402 A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients | COPD Patients | active not recruiting | 12 |
| 2025-12-31 est. | P3 | United BioPharma UTHR | NCT03149211 To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults | HIV-1 Infection | withdrawn | |
| 2025-12-31 | P3 | United Therapeutics UTHR | NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseas | completed | 687 |
| 2025-12-31 | P1/P2 | RemeGen Co., Ltd. | NCT04175847 A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | Solid Tumor | completed | 198 |
| 2025-12-31 est. | P2 | Vasgene Therapeutics, Inc | NCT04486781 A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma | Metastatic Urothelial Carcinoma | unknown | 38 |
| 2025-12-31 est. | P3 | Philogen S.p.A. | NCT04650984 A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma | Soft Tissue Sarcoma | unknown | 102 |
| 2025-12-31 est. | P2 | MitoImmune Therapeutics | NCT04651634 MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients | Head and Neck Squamous Cell Carcinoma; Oral Mucositis | active not recruiting | 60 |
| 2025-12-31 est. | P2 | HUYABIO International, LLC. | NCT04680026 A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) | Atrial Fibrillation | active not recruiting | 150 |
| 2025-12-31 est. | P1/P2 | Sardocor Corp. | NCT04703842 Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction | Congestive Heart Failure; Heart Failure, Systolic; Heart Failure; HFrEF - Heart Failure With Reduced | recruiting | 57 |
| 2025-12-31 | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT04720716 A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | Hepatocellular Carcinoma | completed | 344 |
| 2025-12-31 est. | P1/P2 | NanoRay Biotech Co., Ltd. | NCT04807257 Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment | Malignant Fungating Wound | recruiting | 18 |
| 2025-12-31 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04955834 A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes | Type 2 Diabetes | unknown | 344 |
| 2025-12-31 | P1/P2 | ExCellThera inc. | NCT04990323 US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies | High Risk Myeloid Malignancies; Cord Blood Transplant | completed | 13 |
| 2025-12-31 | P3 | AstraZeneca AZN | NCT05043090 Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC | Papillary Renal Cell Carcinoma | active not recruiting | 148 |
| 2025-12-31 | P3 | Bayer | NCT05047263 A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease | Non-diabetic Chronic Kidney Disease | completed | 1584 |
| 2025-12-31 est. | P3 | KeifeRx, LLC | NCT05143528 Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease | Alzheimer Disease | unknown | 1275 |
| 2025-12-31 est. | P1/P2 | Shanghai EpimAb Biotherapeutics Co., Ltd. | NCT05176665 EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | Neoplasms; Neoplasm Metastasis; Metastatic Gastrointestinal Carcinoid Tumor | unknown | 152 |
| 2025-12-31 | P2 | Akeso | NCT05256472 A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma; First-line Treatment | completed | 28 |
| 2025-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05280626 First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP | Diffuse Large B-Cell Lymphoma | not yet recruiting | 100 |
| 2025-12-31 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05353361 A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer | Breast Cancer | unknown | 402 |
| 2025-12-31 est. | P2 | OBI Pharma, Inc | NCT05442060 To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small C | Non-small Cell Lung Cancer | recruiting | 60 |
| 2025-12-31 est. | P3 | EpicentRx, Inc. | NCT05566041 A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer | Carcinoma, Small Cell Lung | unknown | 292 |
| 2025-12-31 | P2 | RemeGen Co., Ltd. | NCT05628857 A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor | Digestive Cancer | completed | 29 |
| 2025-12-31 est. | P1/P2 | Minghui Pharmaceutical Pty Ltd | NCT05642949 Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor | unknown | 400 |
| 2025-12-31 est. | P1/P2 | HotSpot Therapeutics, Inc | NCT05662397 A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Solid Tumor, Adult; Relapsed Cancer; Refractory Cancer | active not recruiting | 77 |
| 2025-12-31 | P1/P2 | Sonnet BioTherapeutics | NCT05756907 Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | Advanced Solid Tumor; Platinum-resistant Ovarian Cancer | terminated | 40 |
| 2025-12-31 | P1/P2 | GeneCradle Inc | NCT05793307 Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug | Pompe Disease Infantile-Onset | active not recruiting | 16 |
| 2025-12-31 est. | P2 | Hansoh BioMedical R&D Company | NCT05830123 ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas | Osteosarcoma; Sarcoma | recruiting | 170 |
| 2025-12-31 est. | P2 | Orexa BV | NCT05923086 Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy. | Ileus Postoperative | unknown | 126 |
| 2025-12-31 | P1/P2 | NervGen Pharma NGEN | NCT05965700 NVG-291 in Spinal Cord Injury Subjects | Spinal Cord Injuries; Chronic Spinal Cord Injury; Subacute Spinal Cord Injury | completed | 24 |
| 2025-12-31 est. | P3 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT06004856 Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia | Chronic Primary Immune Thrombocytopenia (ITP) | unknown | 195 |
| 2025-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT06006390 CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | Gastric Cancer; Colon Cancer; Rectal Cancer; Esophageal Cancer; Pancreas Cancer; Lung Cancer; Breast | unknown | 60 |
| 2025-12-31 est. | P2 | Hansoh BioMedical R&D Company | NCT06014190 HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer | recruiting | 460 |
| 2025-12-31 est. | P1/P2 | RemeGen Co., Ltd. | NCT06016062 A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | Solid Tumor | recruiting | 221 |
| 2025-12-31 est. | P2 | Jiangsu Renocell Biotech Company | NCT06058078 RY_SW01 Cell Injection Therapy in Active Lupus Nephritis | Lupus Nephritis | recruiting | 60 |
| 2025-12-31 est. | P1/P2 | Jiangsu Renocell Biotech Company | NCT06058091 RY_SW01 Cell Injection Therapy in Systemic Sclerosis | Systemic Sclerosis | recruiting | 81 |
| 2025-12-31 est. | P2 | CellSight Technologies, Inc. | NCT06107374 Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG | Advanced Non Small Cell Lung Cancer | unknown | 20 |
| 2025-12-31 | P2 | RemeGen Co., Ltd. | NCT06173037 RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | Primary Peritoneal Cancer; Fallopian Tube Cancer; Epithelial Ovarian Cancer | completed | 43 |
| 2025-12-31 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06173999 A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma | Peripheral T-cell Lymphoma | unknown | 100 |
| 2025-12-31 est. | P1/P2 | Guangzhou Jiayin Biotech Ltd | NCT06183814 A Study of EXG102-031 in Participants With wAMD | Neovascular Age-related Macular Degeneration | unknown | 42 |
| 2025-12-31 est. | P2 | Dizal Pharmaceuticals | NCT06276283 DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) | Non-small Cell Lung Cancer | recruiting | 60 |
| 2025-12-31 est. | P1/P2 | MB PHARMA s.r.o. | NCT06319235 Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® | Surgical Site Infection; Staphylococcus Aureus Infection; Pseudomonas Aeruginosa Infection; Bacteria | unknown | 52 |
| 2025-12-31 | P2 | Fulgent Pharma LLC. | NCT06332092 FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | active not recruiting | 46 |
| 2025-12-31 est. | P3 | Valenta Pharm JSC | NCT06379542 Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections | Acute Respiratory Infection | unknown | 252 |
| 2025-12-31 | P3 | RDC Clinical Pty Ltd | NCT06440252 Effectiveness of a Grape Seed Extract on Circulatory Measures in Healthy Adults | Circulatory; Change | completed | 35 |
| 2025-12-31 est. | P2 | Shanghai Bao Pharmaceuticals Co., Ltd. | NCT06607016 A Clinical Trial With KJ103 in Anti-GBM Disease | Anti-Glomerular Basement Membrane Disease | active not recruiting | 12 |
| 2025-12-31 est. | P2 | BeBetter Med Inc | NCT06706713 Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer; EGFR Exon 20 Insertion Mutation | recruiting | 200 |
| 2025-12-31 | P3 | Visirna Therapeutics HK Limited | NCT06712771 A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients | Homozygous Familial Hypercholesterolemia (HoFH) | active not recruiting | 46 |
| 2025-12-31 est. | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT06737081 SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies | Anemia | recruiting | 60 |
| 2025-12-31 est. | P3 | NPO Petrovax | NCT06834100 Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug | Infections; Meningococcal | recruiting | 240 |
| 2025-12-31 est. | P2 | Shanghai JMT-Bio Inc. | NCT06892431 JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer | Recurrent or Metastatic Nasopharyngeal Cancer; Patients Who Have Experienced Treatment Failure at Le | not yet recruiting | 150 |
| 2025-12-31 est. | P2 | Jianmin Pharmaceutical Group Co., LTD. | NCT06932328 Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical Trial | Acute Pharyngitis | recruiting | 216 |
| 2025-12-31 | P1/P2 | Ariceum Therapeutics GmbH | NCT06939036 Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) | Small Cell Lung Cancer Extensive Stage; Merkel Cell Carcinoma | terminated | 2 |
| 2025-12-31 est. | P3 | Avizor SA | NCT06985875 Clinical Trial for the Evaluation of Safety and Efficacy of Drop 0.4% | Eye Dryness | not yet recruiting | 79 |
| 2025-12-31 est. | P3 | BeBetter Med Inc | NCT06998108 Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breas | HR+/HER2- Locally Advanced, Metastatic Breast Cancer | recruiting | 330 |
| 2025-12-31 est. | P3 | Daewoong Pharmaceutical Co. LTD. | NCT07013279 Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines | Glabellar Lines | not yet recruiting | 324 |
| 2025-12-31 est. | P3 | Sinotau Pharmaceutical Group | NCT07115238 Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD | Alzheimer Disease; Neurofibrillary Tangle | recruiting | 354 |
| 2025-12-31 | P2/P3 | Shandong Suncadia Medicine Co., Ltd. | NCT07185594 A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery | Postoperative Analgesia | completed | 156 |
| 2025-12-31 est. | P2 | Luye Pharma Group Ltd. | NCT07236476 Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART) | Assisted Reproduction | active not recruiting | 90 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.